Latest News
Acer makes headway in SEA markets with VeriSee DR (Diabetic Retinopathy) medical software
2021-06-30

VeriSee DR, Acer's AI-assisted diagnostic software for ophthalmology, has been approved by Indonesia Ministry of Health, following its medical device clearance gained in Taiwan and Thailand.

VeriSee allows up to 1,000 fundus images to upload at once, analysis files it generates can be accessed without connecting to Internet, providing a convenient yet efficient solution to improve diabetes care. This medical software can be integrated with hospital information systems (e.g. PACS, HIS) and facilitates inter-departmental care.    

Acer indicated that more than one-third of patients with diabetes worldwide are at risk of retinopathy but diagnosis could be neglected as retinopathy shows no symptoms in early stage of development. Indonesia was the 4th largest nation in Asia and the 7th in the world with diabetic patients as per the data in 2019 (10 million), cost to patients could be large at a sign of retinopathy.

In addition to Thailand and Indonesia, the rollout of VeriSee in SEA markets is ongoing with filings for the approval of medical device, as part of Acer’s objectives of driving smart healthcare and growing the influence in diabetes care by taking advantage of its strength in information technology.

VeriSee has been adopted by five medical centres and several clinics in Taiwan.

Source in Chinese: https://tw.stock.yahoo.com/

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978